ABSTRACT
Alzheimer’s disease and related dementias (ADRD) are multifactorial diseases. For efficient treatment of ADRD,
a better understanding of various factors leading to disease etiology is important. In recent years, there are
increased appreciation of vascular contributions to cognitive impairment and dementia (VCID) in the
development and progression of ADRD. While previous studies have examined multiple mechanisms
contributing to vascular dysfunction, little is known about the functional important of extracellular pH in this
process. However, functional MRI imaging shows that brain acidosis not only occurs in dementia patients but
also exhibits positive correlation with disease severity. In our preliminary study, we further showed that a 5XFAD
mouse model of dementia exhibited chronic brain acidosis. In addition, brain acidosis is prominent and persistent
following ischemia and traumatic brain injury, which predispose the development of dementia later in life. In
contrast to the prevalence of brain pH reduction in these conditions, there is a dearth of knowledge on brain acid
signaling in vascular dementia. To fill in this gap in knowledge, this Supplement application will take a unique
angle and focus on acid (proton)-mediated signaling through GPR4, a proton-sensitive GPCR which is present
in brain microvascular endothelial cells (BMEC). Using the 5XFAD mouse and a novel conditional GPR4
knockout mouse, this application will determine whether genetic ablation of GPR4 in endothelium alleviates
cognitive impairment and neuroinflammation in the 5XFAD mouse model of dementia. To generate more insights
into dementia and brain pH, this application will determine age-dependent changes in brain pH in the 5XFAD
mice. Further, this application will further investigate molecular signaling underlying the observed changes and
perform an unbiased transcriptome analysis in BMEC cells isolated from the 5XFAD animals. The results
obtained will lay the groundwork for future in-depth mechanistic as well as translational studies of targeting this
novel pathway in ADRD.